Prescription opioid use: Patient characteristics and misuse in community pharmacy

Journal of the American Pharmacists Association

Volumn 56, Issue 3, 2016, Pages 248-256.e6

  Cochran, Gerald ^a   Bacci, Jennifer L ^b   Ylioja, Thomas ^a   Hruschak, Valerie ^a   Miller, Sharon ^a   Seybert, Amy L ^a   Tarter, Ralph ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCODONE; HYDROMORPHONE; ILLICIT DRUG; METHADONE; MORPHINE; OPIATE; OXYCODONE; NARCOTIC ANALGESIC AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CONVENIENCE SAMPLE; DEPRESSION; DRUG MISUSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PAIN; PENNSYLVANIA; PHARMACY; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; RURAL POPULATION; SCREENING; HEALTH STATUS; MIDDLE AGED; OPIOID-RELATED DISORDERS; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; URBAN POPULATION;

ADULT; ANALGESICS, OPIOID; FEMALE; HEALTH STATUS; HUMANS; MALE; MENTAL HEALTH; MIDDLE AGED; OPIOID-RELATED DISORDERS; PAIN; PENNSYLVANIA; PHARMACIES; PRESCRIPTION DRUG MISUSE; RURAL POPULATION; SOCIOECONOMIC FACTORS; URBAN POPULATION;

EID: 84969141947     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1016/j.japh.2016.02.012     Document Type: Article

References (66)

1. Manchikanti L, Fellows B, Ailinani H, et al. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician. 2010;12(5):401-435.
2. Substance Abuse and Mental Health Services Administration. Results from the 2012 national survey on drug use and health: summary of national findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
3. Centers for Disease Control and Prevention. Morbidity and mortality weekly report. Vital signs: overdoses of prescription opioid pain relieversdUnited States, 1999-2008. Atlanta, GA: Centers for Disease Control and Prevention; 2011.
4. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008;11(2 suppl):S63-88.
5. White AG, Birnbaum HG, Schiller M, et al. Analytic models to identify patients at risk for prescription opioid abuse. Am J Manag Care. 2009;15(12):897-906.
6. Sullivan MD, Edlund MJ, Fan M, et al. Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and Medicaid insurance plans: the TROUP study. Pain. 2010;150(2): 332-339.
7. Rice JB, White AG, Birnbaum HG, et al. A model to identify patients at risk for prescription opioid abuse, dependence, and misuse. Pain Med. 2012;13(9):1162-1173.
8. Becker WC, Sullivan LE, Tetrault JM, et al. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2008;94(1): 38-47.
9. Amari E, Rehm J, Goldner E, et al. Nonmedical prescription opioid use and mental health and pain comorbidities: a narrative review. Can J Psychiatry. 2011;56(8):495-502.
10. Braker LS, Reese AE, Card RO, et al. Screening for potential prescription opioid misuse in a Michigan Medicaid population. Fam Med. 2009;41(10):729-734.
11. Novak SP, Herman-Stahl M, Flannery B, et al. Physical pain, common psychiatric and substance use disorders, and the non-medical use of prescription analgesics in the United States. Drug Alcohol Depend. 2009;100(1-2):63-70.
12. Hudson TJ, Edlund MJ, Steffick DE, et al. Epidemiology of regular prescribed opioid use: results from a national, population-based survey. J Pain Symptom Manage. 2008;36(3):280-288.
13. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva. 2009.
14. Centers for Disease Control and Prevention. Underlying cause of death 1999-2013 on CDC Wonder online database, released 2015. Data are from the Multiple Cause of Death Files, 1999-2013, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Altanta, GA: Centers for Disease Control and Prevention; 2015.
15. Centers for Disease Control and Prevention. Prescription drug overdose data: deaths from prescription opioid overdose. Available at http://www.cdc.gov/drugoverdose/data/overdose.html. Accessed July 16, 2015.
16. Havens JR, Oser CB, Leukefeld CG, et al. Differences in prevalence of prescription opiate misuse among rural and urban probationers. Am J Drug Alcohol Abuse. 2007;33(2):309-317.
17. Jann M, Kennedy WK, Lopez G. Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics. J Pharm Pract. 2014;27(1):5-16.
18. Young AM, Havens JR, Leukefeld CG. A comparison of rural and urban nonmedical prescription opioid users' lifetime and recent drug use. Am J Drug Alcohol Abuse. 2012;38(3):220-227.
19. Centers for Disease Control and Prevention. Policy impact: prescription drug overdose state rates. Available at http://www.cdc.gov/HomeandRecreationalSafety/rxbrief/states.html. Accessed December 7, 2011.
20. Birnbaum HG, White AG, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657-667.
21. Cochran G, Field C, Lawson K. Pharmacists who screen and discuss opioid misuse with patients: future directions for research and practice. J Pharm Pract. 2014;28(4):404-412.
22. Cochran G, Field C, Lawson K, et al. Pharmacists' knowledge, attitudes and beliefs regarding screening and brief intervention for prescription opioid abuse: a survey of Utah and Texas pharmacists. J Pharm Health Serv Res. 2013;4(2):71-79.
23. Cochran G, Erickson C, Field C, et al. Prescription opioid misuse and Texas pharmacies. Bethesda, MD: Association for Medical Education and Research in Substance Abuse Annual Conference; November 2013.
24. Cochran G, Field C, Lawson K, et al. Rx opioid abuse: the role of pharmacists. Palm Springs, CA: College on Problems of Drug Dependence Annual Meeting; June 2012.
25. Drug Chain Review. Pharmacists receive high marks on trust. Chain Drug Rev. 2012;34(21):2.
26. Centers for Disease Control and Prevention. Select features of state pharmacist collaborative practice laws. Atlanta, GA: Centers for Disease Control and Prevention; 2013.
27. Inciardi JA, Surratt HL, Kurtz SP, et al. Mechanisms of prescription drug diversion among drug-involved club and street-based populations. Pain Med. 2007;8(2):171-183.
28. Cicero T, Kurtz S, Surratt H, et al. Multiple determinants of specific modes of prescription opioid diversion. J Drug Issues. 2011;41(2):283-304.
29. Cochran G, Rubinstein J, Bacci JL, et al. Screening community pharmacy patients for risk of prescription opioid misuse. J Addict Med. 2015;9(5): 411-416.
30. Cochran G, Rubinstein J, Bacci JL, et al. Community pharmacy and opioid pain medication: screening patients who misuse or are at risk for misuse. Association for Medical Education and Research in Substance Abuse Annual Conference; November 2015.
31. Substance Abuse and Mental Health Services Administration. Substate estimates of substance use and mental disorders from the 2010-2012 national surveys on drug use and health: results and detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.
32. Knisely JS, Wunsch MJ, Cropsey KL, et al. Prescription opioid misuse index: a brief questionnaire to assess misuse. J Subst Abuse Treat. 2008;35(4):380-386.
33. Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. J Subst Abuse Treat. 2007;32(2):189-198.
34. Skinner HA. Guide for using the Drug Abuse Screening Test (DAST). York University, Toronto.
35. Gavin DR, Ross HE, Skinner HA. Diagnostic validity of the Drug Abuse Screening Test in the assessment of DSM-III drug disorders. Br J Addict. 1989;84(3):301-307.
36. Williams EC, Lapham GT, Hawkins EJ, et al. Variation in documented care for unhealthy alcohol consumption across race/ethnicity in the Department of Veterans Affairs Healthcare System. Alcohol Clin Exp Res. 2012;36(9):1614-1622.
37. Bush K, Kivlahan DR, McDonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16): 1789-1795.
38. Bradley KA, DeBenedetti AF, Volk RJ, et al. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31(7): 1208-1217.
39. Jakobsson U, Westergren A, Lindskov S, et al. Construct validity of the SF-12 in three different samples. J Eval Clin Pract. 2012;18(3):560-566.
40. Maruish M, DeRosa M. A guide to the integration of certified Short Form survey scoring and data quality evaluation capabilities. Lincoln, RI. 2009.
41. Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11): 1284-1292.
42. Corson K, Gerrity MS, Dobscha SK. Screening for depression and suici-dality in a VA primary care setting: 2 items are better than 1 item. Am J Manag Care. 2004;10(11 pt 2):839.
43. van Dam D, Ehring T, Vedel E, et al. Validation of the Primary Care Post-traumatic Stress Disorder screening questionnaire (PC-PTSD) in civilian substance use disorder patients. J Subst Abuse Treat. 2010;39(2):105-113.
44. Ouimette P, Wade M, Prins A, et al. Identifying PTSD in primary care: comparison of the Primary CareePTSD Screen (PC-PTSD) and the General Health Questionnaire-12 (GHQ). J Anxiety Disord. 2008;22(2):337-343.
45. Prins A, Ouimette P, Kimerling R, et al. The Primary Care PTSD screen (PC-PTSD): development and operating characteristics. Prim Care Psychiatry. 2003;9:99-114.
46. StataCorp. Stata SE. College Station, TX. 2015.
47. Algren DA, Monteilh CP, Punja M, et al. Fentanyl-associated fatalities among illicit drug users in Wayne County, Michigan (July 2005eMay 2006). J Med Toxicol. 2013;9(1):106-115.
48. Betts KS, McIlwraith F, Dietze P, et al. Can differences in the type, nature or amount of polysubstance use explain the increased risk of non-fatal overdose among psychologically distressed people who inject drugs? Drug Alcohol Depend. 2015;154:76-84.
49. Jones JD, Vosburg SK, Manubay JM, et al. Oxycodone abuse in New York City: characteristics of intravenous and intranasal users. Am J Addict. 2011;20(3):190-195.
50. Potter JS, Hennessy G, Borrow JA, et al. Substance use histories in patients seeking treatment for controlled-release oxycodone dependence. Drug Alcohol Depend. 2004;76(2):213-215.
51. Visconti AJ, Santos GM, Lemos NP, et al. Opioid overdose deaths in the city and county of San Francisco: prevalence, distribution, and disparities. J Urban Health. 2015;92(4):758-772.
52. Wang KH, Becker WC, Fiellin DA. Prevalence and correlates for nonmedical use of prescription opioids among urban and rural residents. Drug Alcohol Depend. 2013;127(1-3):156-162.
53. Gudin JA, Mogali S, Jones JD, et al. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013;125(4):115-130.
54. Johnson EM, Lanier WA, Merrill RM, et al. Unintentional prescription opioid-related overdose deaths: description of decedents by next of kin or best contact. Utah, 2008-2009. J Gen Intern Med. 2013;28(4): 522-529.
55. Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med. 2011;12(Suppl 2):S26-S35.
56. Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician. 2014;17(2):E119-E128.
57. Schuckman H, Hazelett S, Powell C, et al. A validation of self-reported substance use with biochemical testing among patients presenting to the emergency department seeking treatment for backache, headache, and toothache. Subst Use Misuse. 2008;43(5):589-595.
58. Pringle JL, Boyer A, Conklin MH, et al. The Pennsylvania Project: pharmacist intervention improved medication adherence and reduced health care costs. Health Aff. 2014;33(8):1444-1452.
59. Khan NS, Norman IJ, Dhital R, et al. Alcohol brief intervention in community pharmacies: a feasibility study of outcomes and customer experiences. Int J Clin Pharm. 2013;35(6):1178-1187.
60. Bacci JL, McGrath SH, Pringle JL, et al. Implementation of targeted medication adherence interventions within a community chain pharmacy practice: the Pennsylvania Project. J Am Pharm Assoc (2003). 2014;54(6):584-593.
61. Cerulli J, Zeolla MM. Impact and feasibility of a community pharmacy bone mineral density screening and education program. J Am Pharm Assoc (2003). 2004;44(2):161-167.
62. Cochran G, Gordon AJ, Field C, et al. Developing a framework of care for opioid medication misuse in community pharmacy. Res Social Adm Pharm. 2016;12(2):293-301.
63. Pharmacy Quality Allianace. PQA performance measures. Springfield, VA: Pharmacy Quality Alliance; 2015.
64. Merlo LJ, Cummings SM, Cottler LB. Recovering substance-impaired pharmacists' views regarding occupational risks for addiction. J Am Pharm Assoc (2003). 2012;52(4):480-491.
65. American Association of Colleges of Pharmacy. Substance abuse: the pharmacy educator's role in prevention and recovery. Guidelines for the development of addiction and related disorders policies for colleges and schools of pharmacy. Alexandria, VA: American Association of Colleges of Pharmacy.
66. Code of Federal Regulations, US. Federal register volume 79, number 163; 2014.